Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients
We compared three different chemotherapy regimens containing epirubicin in hormonerefractory prostate cancer (HRPC) patients. Sixty-nine patients with HRPC were randomized into three groups. The first group (22 patients) received 30 mg/m2/week i.v. epirubicin for 8 weeks. The second group (24 patien...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2008.90 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849408053408956416 |
|---|---|
| author | Hamit Ersoy Orhan Yigitbası Levent Sagnak Hikmet Topaloglu Ahmet Kiper |
| author_facet | Hamit Ersoy Orhan Yigitbası Levent Sagnak Hikmet Topaloglu Ahmet Kiper |
| author_sort | Hamit Ersoy |
| collection | DOAJ |
| description | We compared three different chemotherapy regimens containing epirubicin in hormonerefractory prostate cancer (HRPC) patients. Sixty-nine patients with HRPC were randomized into three groups. The first group (22 patients) received 30 mg/m2/week i.v. epirubicin for 8 weeks. The second group (24 patients) received 30 mg/m2/week i.v. epirubicin for 8 weeks followed by monthly maintenance therapy for 4–6 months. The third group (23 patients) received oral estramustine phosphate (EMP) at a dose of 840 mg/day together with weekly and monthly maintenance epirubicin. The response rates, mean survival times, and toxicity were determined. Within the first 3 months, pain and performance scores were improved by at least one degree in all the groups. One patient in group two and three patients in group three had complete response. Partial response rates were 23% in group 1, 25% in group 2, and 17% in group 3. Stable disease rates were 41% in group 1, 33% in group 2, and 26% in group 3. The progression rates within the first 3 months were 36% in group 1, 38% in group 2, and 44% in group 3. None of the patients developed complications that were significant enough to terminate the treatment. Two patients in group 3 died of cardiotoxicity. The mean survival times were 10.1, 15.8, and 16.1 months in groups 1, 2, and 3, respectively. It was determined that weekly and maintenance epirubicin treatment protocol, and estramustine treatment protocol in addition to this treatment, was only meaningfully more effective against weekly epirubicin treatment in the statistical sense (0.01 < p < 0.05). However, due to the complications of EMP, which influence the quality of life, we believe that this was usable only when measures were adopted against these effects. |
| format | Article |
| id | doaj-art-3f1fc6b0d93749049cdc4d4364b4484f |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-3f1fc6b0d93749049cdc4d4364b4484f2025-08-20T03:35:53ZengWileyThe Scientific World Journal1537-744X2008-01-01858659710.1100/tsw.2008.90Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer PatientsHamit Ersoy0Orhan Yigitbası1Levent Sagnak2Hikmet Topaloglu3Ahmet Kiper4Ankara Diskapi Education and Research Hospital, 3rd Urology Clinic, Ankara, TurkeyAnkara Diskapi Education and Research Hospital, 1st Urology Clinic, Ankara, TurkeyAnkara Diskapi Education and Research Hospital, 3rd Urology Clinic, Ankara, TurkeyAnkara Diskapi Education and Research Hospital, 3rd Urology Clinic, Ankara, TurkeyMustafa Kemal University, Department of Urology, Hatay, TurkeyWe compared three different chemotherapy regimens containing epirubicin in hormonerefractory prostate cancer (HRPC) patients. Sixty-nine patients with HRPC were randomized into three groups. The first group (22 patients) received 30 mg/m2/week i.v. epirubicin for 8 weeks. The second group (24 patients) received 30 mg/m2/week i.v. epirubicin for 8 weeks followed by monthly maintenance therapy for 4–6 months. The third group (23 patients) received oral estramustine phosphate (EMP) at a dose of 840 mg/day together with weekly and monthly maintenance epirubicin. The response rates, mean survival times, and toxicity were determined. Within the first 3 months, pain and performance scores were improved by at least one degree in all the groups. One patient in group two and three patients in group three had complete response. Partial response rates were 23% in group 1, 25% in group 2, and 17% in group 3. Stable disease rates were 41% in group 1, 33% in group 2, and 26% in group 3. The progression rates within the first 3 months were 36% in group 1, 38% in group 2, and 44% in group 3. None of the patients developed complications that were significant enough to terminate the treatment. Two patients in group 3 died of cardiotoxicity. The mean survival times were 10.1, 15.8, and 16.1 months in groups 1, 2, and 3, respectively. It was determined that weekly and maintenance epirubicin treatment protocol, and estramustine treatment protocol in addition to this treatment, was only meaningfully more effective against weekly epirubicin treatment in the statistical sense (0.01 < p < 0.05). However, due to the complications of EMP, which influence the quality of life, we believe that this was usable only when measures were adopted against these effects.http://dx.doi.org/10.1100/tsw.2008.90 |
| spellingShingle | Hamit Ersoy Orhan Yigitbası Levent Sagnak Hikmet Topaloglu Ahmet Kiper Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients The Scientific World Journal |
| title | Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients |
| title_full | Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients |
| title_fullStr | Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients |
| title_full_unstemmed | Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients |
| title_short | Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients |
| title_sort | comparison of three different chemotherapy regimens containing epirubicin in hormone refractory prostate cancer patients |
| url | http://dx.doi.org/10.1100/tsw.2008.90 |
| work_keys_str_mv | AT hamitersoy comparisonofthreedifferentchemotherapyregimenscontainingepirubicininhormonerefractoryprostatecancerpatients AT orhanyigitbası comparisonofthreedifferentchemotherapyregimenscontainingepirubicininhormonerefractoryprostatecancerpatients AT leventsagnak comparisonofthreedifferentchemotherapyregimenscontainingepirubicininhormonerefractoryprostatecancerpatients AT hikmettopaloglu comparisonofthreedifferentchemotherapyregimenscontainingepirubicininhormonerefractoryprostatecancerpatients AT ahmetkiper comparisonofthreedifferentchemotherapyregimenscontainingepirubicininhormonerefractoryprostatecancerpatients |